Publication | Closed Access

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

Treatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyVirology100-Week DataVirological SuppressionPharmacotherapyChronic Viral InfectionAntiviral DrugHivMedicinePhase 3